Infección por Helicobacter pylori, causas síntomas y tratamiento
DOI:
https://doi.org/10.23857/dc.v7i6.2393Palabras clave:
Helicobacter, Resistencia a medicamentos, Inhibidores de bomba de protones.Resumen
En el presente artículo, se hace una revisión sobre los aspectos bósicos del tratamiento de Helicobacter pylori, destacando las causas de la falla del tratamiento y se dan estrategias para optimizar el tratamiento de acuerdo a la mejor evidencia publicada. Se destaca la resistencia a los antimicrobianos como la principal causa de fracaso terapéutico, así como también los diferentes compartimentos donde se aloja el microrganismo. Se muestran los principales esquemas actualmente disponibles y la forma de elegir las terapias de primera, segunda, tercera línea y terapias de rescate.Citas
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-9.
O´Coonor A, O´Morain CA, Ford CA. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14(4):230-240.
Malfertheiner P, Megraud F, O´Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Mangement of Helicobacter pylori infection:The Maastricht V/Florence Consensus Report. Gut 2017;66(1):6-30.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-39.
Fallone CA, Chiba N, van Zanten SV. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51-69.
Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV conferencia española de consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2016;39(10):697-721.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.
IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon, France: International Agency for Research on Cancer; 2014 [citado el 7 de julio de 2017]. Disponible en: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/ index.php. [ Links ]
Nam JH, Hong CW, Kim BC, Shin A, Ryu KH, Park BJ, et al. Helicobacter pylori infection is an independent risk factor for colonic adenomatous neoplasms. Cancer Causes Control. 2017;28(2):107-15. [ Links ]
Rokkas T, Gisbert JP, Niv Y, O'Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterol J. 2015;3(6):539-50. [ Links ]
Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta- analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413-7. [ Links ]
Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1120-6. [ Links ]
Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012;47(2):129-35.
Neumeister P, Troppan K, Raderer M. Management of gastric mucosa-associated lymphoid tissue lymphoma. Dig Dis. 2015;33(1):11-8.
Scott D, Weeks D, Melchers K. The life and death of Helicobacter pylori. Gut 1998;43(Suppl 1):S56-S60.
Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):321-31.
Yonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and its involvement for antibiotic resistance. Biomed Res Int. 2015;2015:914791.
Wang YH, LV ZF, Zhong Y, Liu DS, Chen SP, Xie Y. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter. 2017;22(1):e12324.
Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol. 2014;30(6):589-95.
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H.pylori eradication therapies. Helicobacter. 2017;22(4):e12392.
Graham DY, Dore MP. Helicobacter pyloritherapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577-85.
Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Clev Clin J Med. 2017;84(4):310-8.
Villoria A, García P, Calvet X, Gisbert J, Vergara M. Metaanalysis: high dose proton pump inhibtor vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868-77.
Ducoumau A, Bí©ní©jat L, Sifrí© LE, Lehours P, Mí©graud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect. 2016;22(8):715-8.
Thung I, Aramin RH, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33.
Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernández-García T, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin Am J Gastroenterol. 2014;109(4):485-95.
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209-21.
Furuta T, Graham DY. Pharmacologic aspects of eradicaction therapy for Helicobacterpylori infection. Gastroenterol Clin North Am. 2010;39(3):465-80.
Publicado
Cómo citar
Número
Sección
Licencia
Authors retain copyright and guarantee the Journal the right to be the first publication of the work. These are covered by a Creative Commons (CC BY-NC-ND 4.0) license that allows others to share the work with an acknowledgment of the work authorship and the initial publication in this journal.
